On December 18, 2023, the Minister of Health announced the creation of the Canadian Drug Agency. According to the announcement, the Canadian Drug Agency (CDA) “will provide the dedicated leadership and coordination needed to make Canada's drug system more sustainable and better prepared for the future, helping Canadians achieve better health outcomes.” It will be built from the Canadian Agency for Drugs and Technologies in Health (CADTH), in partnership with provinces and territories. The CDA will build on CADTH’s mandate and functions, and will expand them, including improving appropriate prescribing and use of medications, and increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada takes action to address generic drug submission review backlog
Health Canada is not currently meeting its performance standards for the review of some generic drug submissions. On September 1, 2026, Health Canada launched a new webpage, Improving how we review ge...Read More -
PMPRB releases September 2026 NEWSletter
The September NEWSletter also provides information about the PMPRB’s participation in past and future events, as well as NPDUIS research initiative and activities.Read More -
Health Canada provides its quarterly update and PMPRB publishes the 10th edition of the Meds Entry Watch report
On October 15, 2026, Health Canada provided its quarterly update summarizing steps it has taken “to make its regulatory processes more modern and efficient, while maintaining high standards for safety...Read More
